Details

HLA B57 Screen for Abacavir Sensitivity

HLA-B*5701 Screening for Abacavir Hypersensitivity , EPIC: LAB6425, SOFT: CIB57

Specimen Collection Criteria

Collect: One Lavender-top EDTA tube.

Invert several times to mix well. 

Physician Office/Drawsite Specimen Preparation

Do not refrigerate or freeze specimen. Maintain whole blood at room temperature (20-26°C or 68-78.8°F) prior to transport. Transport to the Laboratory within 24 hours of collection.

Preparation for Courier Transport

Transport: Whole blood at room temperature (20-26°C or 68-78.8°F).

Rejection Criteria

  • Unlabeled specimens.
  • Specimens drawn in clot, SST, or Heparin tubes.
  • This test will only be performed once in a lifetime for a patient.

Performed

Monday - Friday, 7:00 a.m. - 5:00 p.m.
Results available within 7 days.

Reference Range

Negative or positive for HLA-B*57:01.

Test Methodology

Sequence Specific Priming (SSP) for HLA Class I Genotyping.

Clinical Utility

The FDA recommends that genetic testing for HLA-B*5701 be performed prior to prescribing the reverse transcriptase inhibitor, Abacavir, to HIV patients. The presence of HLA-B*5701 is associated with a drug-induced hypersensitivity reaction to Abacavir that can be prevented with prior genetic screening.

Clinical Disease

Human Immunodeficiency Virus (HIV).

Reference

  1. Mallal et al. HLA-B*5701 Screening for Hypersensitivity to Abacavir. The New England Journal of Medicine, 358 (6): 568-579, 2008.

CPT Code

81381.

Test Codes

EPIC: LAB6425, SOFT: CIB57

Last Updated

7/11/2019